IGN101 is an antibody-based cancer vaccine directed against epithelial cancers. It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.
- Mechanism
- Curator reviewed
IGN101 consists of 17-1A antibody adsorbed on aluminum hydroxide. The murine monoclonal antibody 17-1A (edrecolomab) binds with low affinity to the epithelial cell adhesion molecule (EpCAM), overexpressed on most epithelial cancers. IGN101 led to a significant reduction of EpCAM positive cells in peripheral blood of patients. Destruction of disseminated tumor cells may lead to a delay or prevention of the development of metastases.
- Primary indication
- Investigated for use/treatment in breast cancer, colorectal cancer, and lung cancer.Curator reviewed
- Code names
- IGN101
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with IGN101, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account